Full Press Release Details
SOUTH SAN FRANCISCO, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company will present two scientific posters at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022, in London, United Kingdom.
| Poster: | Rationale for Evaluation of PLN-74809 Treatment in Participants with Primary Sclerosing Cholangitis in Phase 2A Study INTEGRIS-PSC |
| Presenter: | Éric Lefebvre, M.D., Pliant Therapeutics |
| Session: | Immune-mediated and Cholestatic Disease: Clinical Aspects |
| Date: | June 23, 2022 |
| Time: | 9:00 am - 6:30 pm BST |
This poster summarizes the findings from preclinical studies investigating the antifibrotic activity resulting from dual αvß6 and αvß1 integrin inhibition by PLN-74809 in precision-cut liver slices (PCLivS) from patients with primary sclerosing cholangitis (PSC) and in vivo models of PSC, that supported the rationale for the Phase 2a clinical evaluation of PLN-74809 in participants with large-duct PSC in the ongoing INTEGRIS-PSC study.
| Poster: | Dual Inhibition of Integrins α v ß 6 and α v ß 1 Decreases Portal Pressure and Liver Fibrosis in Rats with Biliary Cirrhosis |
| Presenter: | Philipp Königshofer, DVM, Medical University of Vienna, Vienna |
| Session: | Fibrosis: General Hepatology |
| Date: | June 24, 2022 |
| Time: | 9:00 am – 6:00 pm BST |
This poster investigates the effects of PLN-75068, a dual αvß6 / αvß1 inhibitor tool compound, on liver fibrosis and portal hypertension in rats with cholestatic biliary cirrhosis.
Posters presented at the EASL International Liver Congress™ 2022 will be available on-demand on Pliant’s website under the Publications section at https://pliantrx.com/publications.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.